• Regeneron Announces Phase 2 Results for Garetosmab americanpharmaceuticalreview
    January 14, 2020
    Regeneron Pharmaceuticals announced results from LUMINA-1, a 44-patient, Phase 2, double-blind placebo-controlled trial evaluating garetosmab (REGN2477) in patients with fibrodysplasia ossificans progressiva (FOP).
PharmaSources Customer Service